BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33665734)

  • 1. Validation of aorta-lesion-attenuation difference on preoperative contrast-enhanced computed tomography scan to differentiate between malignant and benign oncocytic renal tumors.
    Grajo JR; Batra NV; Bozorgmehri S; Magnelli LL; Pavlinec J; O'Malley P; Su LM; Crispen PL
    Abdom Radiol (NY); 2021 Jul; 46(7):3269-3279. PubMed ID: 33665734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using Aorta-Lesion-Attenuation Difference on Preoperative Contrast-enhanced Computed Tomography Scan to Differentiate Between Malignant and Benign Renal Tumors.
    Grajo JR; Terry RS; Ruoss J; Noennig BJ; Pavlinec JG; Bozorgmehri S; Crispen PL; Su LM
    Urology; 2019 Mar; 125():123-130. PubMed ID: 30552939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between nuclear grade of renal cell carcinoma and the aorta-lesion-attenuation-difference.
    Grajo JR; Batra NV; Bozorgmehri S; Magnelli LL; O'Malley P; Terry R; Su LM; Crispen PL
    Abdom Radiol (NY); 2021 Dec; 46(12):5629-5638. PubMed ID: 34463815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aorta-Lesion-Attenuation-Difference (ALAD) on contrast-enhanced CT: a potential imaging biomarker for differentiating malignant from benign oncocytic neoplasms.
    Dhyani M; Grajo JR; Rodriguez D; Chen Z; Feldman A; Tambouret R; Gervais DA; Arellano RS; Hahn PF; Samir AE
    Abdom Radiol (NY); 2017 Jun; 42(6):1734-1743. PubMed ID: 28197683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of the Aortic-Lesion-Attenuation-Difference (ALAD) and Peak Early-Phase Enhancement Ratio (PEER) to differentiate benign from malignant renal masses.
    Kahn AE; Lomax SJ; Bajalia EM; Ball CT; Thiel DD
    Can J Urol; 2020 Aug; 27(4):10278-10284. PubMed ID: 32861252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small renal masses (≤ 4 cm): differentiation of oncocytoma from renal clear cell carcinoma using ratio of lesion to cortex attenuation and aorta-lesion attenuation difference (ALAD) on contrast-enhanced CT.
    Gentili F; Bronico I; Maestroni U; Ziglioli F; Silini EM; Buti S; de Filippo M
    Radiol Med; 2020 Dec; 125(12):1280-1287. PubMed ID: 32385827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT.
    Young JR; Margolis D; Sauk S; Pantuck AJ; Sayre J; Raman SS
    Radiology; 2013 May; 267(2):444-53. PubMed ID: 23382290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep learning and radiomics: the utility of Google TensorFlow™ Inception in classifying clear cell renal cell carcinoma and oncocytoma on multiphasic CT.
    Coy H; Hsieh K; Wu W; Nagarajan MB; Young JR; Douek ML; Brown MS; Scalzo F; Raman SS
    Abdom Radiol (NY); 2019 Jun; 44(6):2009-2020. PubMed ID: 30778739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative computer-aided diagnostic algorithm for automated detection of peak lesion attenuation in differentiating clear cell from papillary and chromophobe renal cell carcinoma, oncocytoma, and fat-poor angiomyolipoma on multiphasic multidetector computed tomography.
    Coy H; Young JR; Douek ML; Brown MS; Sayre J; Raman SS
    Abdom Radiol (NY); 2017 Jul; 42(7):1919-1928. PubMed ID: 28280876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of clear from non-clear cell renal cell carcinoma using CT washout formula.
    Kopp RP; Aganovic L; Palazzi KL; Cassidy FH; Sakamoto K; Derweesh IH
    Can J Urol; 2013 Jun; 20(3):6790-7. PubMed ID: 23783049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of oncocytoma and renal cell carcinoma in small renal masses (<4 cm): the role of 4-phase computerized tomography.
    Bird VG; Kanagarajah P; Morillo G; Caruso DJ; Ayyathurai R; Leveillee R; Jorda M
    World J Urol; 2011 Dec; 29(6):787-92. PubMed ID: 20717829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An In-vivo Prospective Study of the Diagnostic Yield and Accuracy of Optical Biopsy Compared with Conventional Renal Mass Biopsy for the Diagnosis of Renal Cell Carcinoma: The Interim Analysis.
    Buijs M; Wagstaff PGK; de Bruin DM; Zondervan PJ; Savci-Heijink CD; van Delden OM; van Leeuwen TG; van Moorselaar RJA; de la Rosette JJMCH; Laguna Pes MP
    Eur Urol Focus; 2018 Dec; 4(6):978-985. PubMed ID: 29079496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of multidetector computed tomography to differentiate between renal cell carcinoma and oncocytoma. A model validation.
    Paño B; Soler A; Goldman DA; Salvador R; Buñesch L; Sebastià C; Nicolau C
    Br J Radiol; 2020 Nov; 93(1115):20200064. PubMed ID: 32706993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment differentiation of renal cell carcinoma subtypes by CT: the influence of different tumor enhancement measurement approaches.
    Zokalj I; Marotti M; Kolarić B
    Int Urol Nephrol; 2014 Jun; 46(6):1089-100. PubMed ID: 24381132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation between renal oncocytomas and chromophobe renal cell carcinomas using dynamic contrast-enhanced computed tomography.
    Guo K; Ren S; Cao Y; Zhang H; Zhang Y; Gu X; Wang Z
    Abdom Radiol (NY); 2021 Jul; 46(7):3309-3316. PubMed ID: 33710383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voxel-based whole-lesion enhancement parameters: a study of its clinical value in differentiating clear cell renal cell carcinoma from renal oncocytoma.
    Chen F; Gulati M; Hwang D; Cen S; Yap F; Ugwueze C; Varghese B; Desai M; Aron M; Gill I; Duddalwar V
    Abdom Radiol (NY); 2017 Feb; 42(2):552-560. PubMed ID: 27595574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.
    Amin J; Xu B; Badkhshan S; Creighton TT; Abbotoy D; Murekeyisoni C; Attwood KM; Schwaab T; Hendler C; Petroziello M; Roche CL; Kauffman EC
    Clin Cancer Res; 2018 Aug; 24(16):3898-3907. PubMed ID: 29752278
    [No Abstract]   [Full Text] [Related]  

  • 18. Characterization of renal cell carcinoma, oncocytoma, and lipid-poor angiomyolipoma by unenhanced, nephrographic, and delayed phase contrast-enhanced computed tomography.
    Ishigami K; Pakalniskis MG; Leite LV; Lee DK; Holanda DG; Rajput M
    Clin Imaging; 2015; 39(1):76-84. PubMed ID: 25457535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small renal oncocytomas: differentiation with multiphase CT.
    Gakis G; Kramer U; Schilling D; Kruck S; Stenzl A; Schlemmer HP
    Eur J Radiol; 2011 Nov; 80(2):274-8. PubMed ID: 20667676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discrimination of oncocytoma and chromophobe renal cell carcinoma using MRI.
    Akın IB; Altay C; Güler E; Çamlıdağ İ; Harman M; Danacı M; Tuna B; Yörükoğlu K; Seçil M
    Diagn Interv Radiol; 2019 Jan; 25(1):5-13. PubMed ID: 30644365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.